Dr. Martens (LON:DOCS) Shares Down 6.4% – What’s Next?

Dr. Martens plc (LON:DOCS)’s stock price was down 6.4% during mid-day trading on Tuesday . The stock traded as low as GBX 69.90 and last traded at GBX 70.80. Approximately 443,436 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 1,566,484 shares. The stock had previously closed at GBX 75.65.

Analyst Ratings Changes

Several equities research analysts have issued reports on DOCS shares. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Dr. Martens has an average rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Price Performance

The firm has a fifty day moving average of GBX 75.88 and a two-hundred day moving average of GBX 83.26. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The company has a market capitalization of £660.40 million, a PE ratio of 40.19, a PEG ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last announced its quarterly earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Research analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Insider Transactions at Dr. Martens

In other news, insider Robert Hanson acquired 96,000 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were purchased at an average price of GBX 79 per share, for a total transaction of £75,840. Over the last 90 days, insiders have acquired 97,130 shares of company stock valued at $7,673,816. 2.79% of the stock is owned by company insiders.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.